Table 1 Baseline characteristics of RA patients included in the IL-33 ancillary study from the SMART trial and a comparison between the patients in the SMART cohort included in the IL-33 study (cohort 1, n = 111) and the rest of the cohort not assessed for serum IL-33 level (n = 113)
From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Cohort 1 | Patients in the SMART cohort without IL-33 dosage | Whole SMART cohort | Inter-group comparison | |
|---|---|---|---|---|
(n = 111) | (n = 113) | (n = 224) | ||
Age (years) | 56 ± 11 | 56 ± 11 | 56 ± 11 | 0.99 |
Female | 95 (86%) | 92 (81%) | 187 (84%) | 0.401 |
Disease duration (years) | 11 (1–42) | 10 (0.8–45) | 11 (0.8–45) | 0.094 |
DAS28-CRP | 5.8 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 | 0.791 |
HAQ-DI | 1.8 ± 0.6 | 1.8 ± 0.6 | 1.8 ± 0.6 | 0.753 |
Prednisone treatment | 76 (68%) | 88 (78%) | 165 (74%) | 0.11 |
Prednisone dosage (mg/day) | 8 (2–20) | 10 (2–15)* | 10 (2–20)* | 0.243 |
MTX (mg/week) | 14 ± 4 | 14 ± 4 | 14 ± 4 | 0.351 |
Previous biologic: None/mAb/Eta | 8 (7%)/66 (60%)/37(33%) | 7 (6%)/70(62%)/36(32%) | 15 (7%)/136 (61%)/73(33%) | 0.914 |
Positive RF | 76 (69%) | 68 (61%) | 144 (65%) | 0.226 |
Positive anti-CCP | 92 (83%) | 78 (70%) | 170 (76%) | 0.02 |
Serum IgG level (g/L) | 11.8 (4.6–19.2) | 12 (5.4–23.3) | 12 (4.6–23.3) | 0.564 |
CRP level (mg/L) | 12 (0.4–139) | 11 (0.3–102) | 11 (0.3–139) | 0.938 |
Radiographic erosions | 100 (90%) | 98 (87%) | 198 (88%) | 0.432 |
MTX duration (years) | 3.6 (0.1–20.8) | 3.2 (0.3–20.5) | 3.5 (0.1–20.8) | 0.856 |
Time since last anti-TNF (months) | 2.7 (0.6–64.4) | 2.8 (1.2–73.6) | 2.7 (0.6–73.6) | 0.458 |